The Common Infrastructure for National Cohorts in Europe, Canada, and Africa (CINECA) project looks to harmonize ontologies and create an interoperability platform for global genomics research.
Proposals from two HHS agencies look to encourage patient access to data and interoperability in research and clinical practice, including Sync for Genes.
Following the launch of GenoVic last year, the organization is working to get more centers on the platform and figure out its role in an A$500M national initiative.
The alliance has also deepened its ongoing partnership with ELIXIR, while continuing to roll out new tools and standards for genomic data discovery, analysis, and interpretation.
After formalizing the FHIR interoperability standard, HL7 offers data-usage examples to nonacademic providers looking to start or advance precision medicine programs.
After giving up on the cryptocurrency idea, LunaDNA looks to "invert the research equation" by letting patients control and sell their genomic and health information.
The new multinational consortium, backed by the EU and Canada, seeks to improve understanding of immune responses and uncover new therapeutic targets.
Funded by a $120M grant, the planned interdisciplinary School of Data Science will dedicate perhaps a quarter of its resources to bioinformatics-related activities.
In Science this week: high-resolution map of human genetic recombination, and more.
The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.
Two researchers are calling for education for scientists on defending facts.
Researchers were among those who marched in London this weekend to call for another vote on Brexit.
Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant.
In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.